As of March 27, 2026, NeuroMetrix Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $4.58, this represents a potential upside of -4897.5%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -4977.7% |
| Potential Upside (10-year) | -4897.5% |
| Discount Rate (WACC) | 4.5% - 5.2% |
Revenue is projected to grow from $3 million in 12-2024 to $4 million by 12-2034, representing a compound annual growth rate of approximately 2.9%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 3 | 49% |
| 12-2025 | 3 | 5% |
| 12-2026 | 3 | 2% |
| 12-2027 | 3 | 5% |
| 12-2028 | 3 | 2% |
| 12-2029 | 4 | 5% |
| 12-2030 | 4 | 3% |
| 12-2031 | 4 | 3% |
| 12-2032 | 4 | 4% |
| 12-2033 | 4 | 3% |
| 12-2034 | 4 | 2% |
Net profit margin is expected to improve from -257% in 12-2024 to -179% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (8) | -257% |
| 12-2025 | (6) | -186% |
| 12-2026 | (6) | -185% |
| 12-2027 | (6) | -183% |
| 12-2028 | (6) | -182% |
| 12-2029 | (7) | -181% |
| 12-2030 | (7) | -180% |
| 12-2031 | (7) | -180% |
| 12-2032 | (7) | -180% |
| 12-2033 | (8) | -180% |
| 12-2034 | (8) | -179% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 1% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 0 |
| 12-2026 | 0 |
| 12-2027 | 0 |
| 12-2028 | 0 |
| 12-2029 | 0 |
| 12-2030 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 28 |
| Days Inventory | 296 |
| Days Payables | 64 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2025 | (8) | (2) | 0 | (0) | (6) |
| 2026 | (8) | (2) | 0 | 0 | (6) |
| 2027 | (9) | (2) | 0 | (0) | (6) |
| 2028 | (9) | (2) | 0 | (0) | (6) |
| 2029 | (9) | (2) | 0 | 0 | (7) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -4977.7% |
| 10-Year DCF (Growth) | 0.00 | -4897.5% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is NeuroMetrix Inc (NURO) a buy or a sell? NeuroMetrix Inc is definitely a sell. Based on our DCF analysis, NeuroMetrix Inc (NURO) appears to be overvalued with upside potential of -4897.5%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $4.58.